WallStreetZenWallStreetZen

NASDAQ: INDP
Indaptus Therapeutics Inc Stock Ownership - Who owns Indaptus Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Indaptus Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Walt Addison LinscottChief Operating Officer2025-12-2254,421$2.03
$110.47kBuy
Jeffrey A. MecklerCo-Chief Executive Officer2025-12-22216,617$2.03
$439.73kBuy
Michael James NewmanCSO and Director2025-12-2252,204$2.03
$105.97kBuy
Nir SassiChief Financial Officer2025-12-2226,758$2.03
$54.32kBuy
Jeffrey A. MecklerChief Executive Officer2025-07-276,068$8.30
$50.38kBuy

1 of 1

INDP insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when INDP insiders and whales buy or sell their stock.

INDP Shareholders

What type of owners hold Indaptus Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Dexcel Pharma Technologies Ltd188.86%4,234,897$7.20MInsider
Michael James Newman65.53%1,469,430$2.50MInsider
Glen R. Anderson58.17%1,304,318$2.22MInsider
Jeffrey A. Meckler10.25%229,929$390.88kInsider
John W. Kozarich6.77%151,761$257.99kInsider
Walt Addison Linscott2.43%54,426$92.52kInsider
Anthony J. Maddaluna2.39%53,570$91.07kInsider
Ubs Group Ag1.29%29,002$49.30kInstitution
Nir Sassi1.19%26,758$45.49kInsider
Avraham Bentzvi1.12%25,100$42.67kInsider

1 of 2

INDP vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
INDP0.42%99.58%Net Buying
AZTR1.39%98.08%
APVO0.56%99.44%Net Buying
MTNB1.45%98.55%
DCOY0.67%99.33%Net BuyingNet Selling
View Top Biotech Stocks

Indaptus Therapeutics Stock Ownership FAQ

Who owns Indaptus Therapeutics?

Indaptus Therapeutics (NASDAQ: INDP) is owned by 1.44% institutional shareholders, 339.37% Indaptus Therapeutics insiders, and 0.00% retail investors. Dexcel Pharma Technologies Ltd is the largest individual Indaptus Therapeutics shareholder, owning 4.23M shares representing 188.86% of the company. Dexcel Pharma Technologies Ltd's Indaptus Therapeutics shares are currently valued at $7.45M.

If you're new to stock investing, here's how to buy Indaptus Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.